Latisse blog posts and news

Brooke Shields Latisse Advertising Slammed By Consumer Reports

Consumer Reports slams Latisse and the Brooke Shields ad that's been then center of the $14.5M Latisse advertising campaign.

With 88% of our readers saying Latisse is "worth it", do you think the Consumer Reports video lacks balance? 

» Read more

Latisse Side Effects: What Are Women Really Experiencing?

The FDA yesterday issued a letter to Allergan regarding their lack of warnings on the Latisse Web site about possible side effects of using the eyelash lengthening product, claiming the company is misleading consumers.

Top rated cosmetic treatment

At RealSelf.com, Latisse turns out to be one of the highest rated procedures, with 86% of those who’ve used Latisse believing it was worth it. Side effects are certainly discussed, yet the most controversy has swirled around whether or not to buy the generic version of Latisse, the glaucoma drug Lumigan.

By way of background, Latisse was approved by the FDA this past December, and since then has become a popular treatment for those looking to enhance their eyelashes.

» Read more

6 Ways To Make Your Latisse Last Longer

No doubt about it: women love their Latisse for the way it lengthens their eyelashes. Our community has given it a resounding thumbs-up, with some serious raves. But one thing Latisse isn't is cheap: about $130 for a two-month supply, if used as directed. That means one drop on one applicator brush for each eye for 60 days.

Still, everyone from RealSelfers to our experts to beauty bloggers have been finding creative ways to make their precious drops of Latisse -- and their dollars -- last a little longer. Here's what they're finding:

1. Use only one Latisse drop -- in the cap -- each day. 

The directions tell you to apply one drop directly to the brush for each eye. To avoid waste, RealSelf's ever-resourceful Eva has crafted her own method: "I put one drop in the cap, and dip the brush in the cap. This way, I can do both eyelids with one drop and one brush." Eva used Latisse to get lush lashes before her wedding -- and said they were "ridiculously long" after three weeks.

» Read more

Q&A Of The Day: How Much Does Latisse Cost?

In today's Q&A of the day, RealSelf user Miss Yates is looking for the answer to a question a lot of our community has been asking:

What's it going to cost me to get longer lashes with Latisse?

As Miss Yates found out, over 30 of our MDs chimed in, and the general consensus is that it's about $120 for a 60-day supply (at least that's what Allergan is suggesting).

Dr. Eric Joseph in West Orange, NJ says he's using a slightly different treatment regimen, so a $120 bottle will last you four months. And SF plastic surgeon Corey Maas, MD is offering it at cost -- $92 for a bottle. And the range (for various amounts) can veer between $72 and $150.

Wherever you get it, watch out for possible side effect that have been reported, as Dr. Arnold Oppenheim points out, including patients "having their blue eyes turn brown."

» Read more

Latisse May Cause Hair To Grow Anywhere

ABC 13 in Houston, Texas reports that Latisse, while working as expected for eyelash lengthening, caused unwanted hair to grow on the face for one woman who didn't wipe off the excess solution after application.

Other reported Latisse side effects include darkening of eyelid skin and a transformation of the eye color.  Houston ophthalmologist, Dr. Linda Pope, tells ABC that "a hazel-colored eye will turn dark brown, and it's not reversible" should Latisse enter the eye. The medical experts posting on RealSelf.com point out that there is no clinical evidence suggesting Latisse has systemic side effects such as vision damage.

» Read more

Star-Studded Latisse Event Raises Money For Make-a-Wish

Allergan introduced the "Latisse Wishes" campaign at a star-studded charity event last week in Hollywood, California. Celebrities Brooke Shields, Marisa Tomei and Mandy Moore attended the benefit to express their support for Make-A-Wish, the non-profit organization that aims to grant wishes for suffering children.

Latisse is Allergan's latest offering and the first drug to be approved by the FDA for the treatment of hypotrichosis, a condition characterized by inadequate eyelashes. The Latisse Wishes campaign was launched with a $500,000 initial contribution to Make-A-Wish.

Hollywood beauty expert and participant Anastasia Soare enthusiastically expressed her support, saying "I constantly work to help make women's beauty wishes come true, and now we can help children's wishes come true through the LATISSE™ Wishes campaign."

» Read more

A Revolution In Eyelashes: Latisse Lash Lengthener

Anastasia Soare, the founder of the Anastasia Beverly Hills cosmetics line, is often referred to as "the definitive brow expert" by beauty industry insiders.

Anastasia recently commented on Latisse eyelash lengthener, a new lash-growing formula available from Allergan, better known for wrinkle reducer Botox and lip plumper Juvederm.

Transformational lash results

Soare states that she's "seen the results of Latisse firsthand and truly believes it's going to change the way women see eyes."

» Read more

Latisse Eyelash Enhancer Enters Marketplace

Last month, the FDA approved Allergan's accidentally discovered eyelash-enhancing drug, Latisse. What started out as a clinical trial for a known glaucoma treatment turned out to have a highly desired side-effect - significantly longer eyelashes.

When the glaucoma eyedrop known as Lumigan entered its third phase of clinical trials, Allergan researchers noticed the drug's eyelash-enhancing effects and the company soon started considering the cosmetic applications that could be derived from it's active ingredient, bimatoprost.

» Read more

Allergan Clears First FDA Hurdle For Eyelash Enhancer

After all the cat-fighting between Athena Cosmetics, Athena Bioscience, DermaQuest, Jan Marini and Allergan (maker of Botox Cosmetic) over their eyelash enhancing formulas, Allergan must be having a nice little chuckle to themselves as an FDA advisory panel—the Dermatologic and Ophthalmic Drugs Advisory Committee—gave their support to Allergan's Latisse on Friday.

» Read more